## Khalid Shoumariyeh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1422344/publications.pdf Version: 2024-02-01



KHALID SHOUMADIVEH

#	Article	IF	CITATIONS
1	Oncogenic JAK2 <sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Science Translational Medicine, 2018, 10, .	12.4	166
2	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematology,the, 2019, 6, e638-e649.	4.6	101
3	Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. Nature Communications, 2020, 11, 1659.	12.8	92
4	MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. Journal of Clinical Oncology, 2019, 37, 2846-2856.	1.6	82
5	Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Science Translational Medicine, 2020, 12, .	12.4	70
6	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1927-1938.	5.7	47
7	Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nature Communications, 2021, 12, 6436.	12.8	45
8	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 81-87.	3.8	42
9	Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. Haematologica, 2020, 105, 2872-2878.	3.5	40
10	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. Lancet Haematology,the, 2021, 8, e194-e204.	4.6	39
11	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia, 2020, 34, 1090-1101.	7.2	34
12	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia, 2019, 33, 1124-1134.	7.2	29
13	Covidâ€19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany. Cancer Medicine, 2020, 9, 8412-8422.	2.8	29
14	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. Leukemia, 2022, 36, 516-524.	7.2	29
15	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. Cancers, 2021, 13, 1151.	3.7	27
16	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. Theranostics, 2021, 11, 292-303.	10.0	26
17	Community-driven development of a modified progression-free survival ratio for precision oncology. ESMO Open, 2019, 4, e000583.	4.5	22
18	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1705-1712.e4.	3.8	13

KHALID SHOUMARIYEH

#	Article	IF	CITATIONS
19	Loss of the Fanconi anemia–associated protein NIPA causes bone marrow failure. Journal of Clinical Investigation, 2020, 130, 2827-2844.	8.2	8
20	Blastic transformation of <i>BCRâ€ABL1</i> positive chronic myeloid leukaemia through acquisition of <i>CBFBâ€MYH11</i> and mutant <i>KIT</i> . British Journal of Haematology, 2020, 190, e339-e343.	2.5	5
21	Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model. Leukemia, 2020, 34, 3242-3255.	7.2	4
22	A novel conditional NPM-ALK-driven model of CD30+ T-cell lymphoma mediated by a translational stop cassette. Oncogene, 2020, 39, 1904-1913.	5.9	3
23	Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures. BMC Cancer, 2021, 21, 173.	2.6	3
24	Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib. Blood and Lymphatic Cancer: Targets and Therapy, 0, , 81.	2.7	2
25	Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies. Journal of Cancer Research and Clinical Oncology, 2021, 148, 331.	2.5	2
26	Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab. Annals of Hematology, 2021, 100, 1637-1640.	1.8	1
27	Metabolic Reprogramming Overcomes T Cell Inhibition By AML Cells. Blood, 2018, 132, 3328-3328.	1.4	0
28	Checkpoint Inhibition in CSF3R Mutated Chronic Neutrophilic Leukemia. Blood, 2018, 132, 3056-3056.	1.4	0
29	The Fanconi Anemia-Associated Protein NIPA Is Essential for the Nuclear Abundance of FANCD2. Blood, 2019, 134, 3741-3741.	1.4	0